首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Leukemia Research

Leukemia Research杂志,由Elsevier Ltd出版,于1977年创刊,Monthly,出版语言English,ISSN:0145-2126,E-ISSN:1873-5835。

投稿咨询
Leukemia Research
Leukemia Research
Leukemia Research
SCI SCIE

杂志介绍

JCR分区
Q2
中科院分区
4区
影响因子
2.4
CiteScore
4.1
期刊收录
SCI、SCIE

Leukemia Research(中文译名:《白血病研究》),ISSN:0145-2126,EISSN:1873-5835,是Elsevier Ltd出版的国际性学术期刊,创刊于1977年,以Monthly形式稳定发行,2026年总发文量约73篇。该刊采用非OA开放访问,学科归属为医学 - 血液学。该刊是医学、肿瘤学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达2.4,2025年期刊CiteScore为4.1,2025年期刊自引率约0%,在中科院期刊分区体系中位列医学大类4区,在所属学科领域具备高学术影响力与国际认可度。Leukemia Research长期聚焦医学、肿瘤学及相关产业的技术应用前沿,平均审稿周期一般,3-6周,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、肿瘤学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,TurkeyUSA、CHINA MAINLAND、Italy、Japan、GERMANY (FED REP GER)、France等为核心发文国家与地区;ISTANBUL UNIVERSITYUNIVERSITY OF TEXAS SYSTEM、HACETTEPE UNIVERSITY、DISKAPI YILDIRIM BEYAZIT TRAINING & RESEARCH HOSPITAL、ASSISTANCE PUBLIQUE HOPITAUX PARIS (APHP)、CHINESE ACADEMY OF MEDICAL SCIENCES - PEKING UNION MEDICAL COLLEGE、HARVARD UNIVERSITY等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
4区
ONCOLOGY 肿瘤学 HEMATOLOGY 血液学
4区 4区
否 否

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
4区
HEMATOLOGY 血液学 ONCOLOGY 肿瘤学
4区 4区
否 否

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
4区
HEMATOLOGY 血液学 ONCOLOGY 肿瘤学
4区 4区
否 否

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:HEMATOLOGY SCIE Q2 51 / 103

51

学科:ONCOLOGY SCIE Q3 214 / 333

35.9

学科:HEMATOLOGY SCIE Q3 54 / 103

48.06

学科:ONCOLOGY SCIE Q3 216 / 333

35.29

2024-2025年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:HEMATOLOGY SCIE Q3 51 / 99

49

学科:ONCOLOGY SCIE Q3 217 / 328

34

学科:HEMATOLOGY SCIE Q3 56 / 100

44.5

学科:ONCOLOGY SCIE Q3 222 / 328

32.47


中国学者近期发文

1
Risk factors and fluid management in tumor lysis syndrome of acute myeloid leukemia: A retrospective stud

Author:Yuan, Fei; Zhao, Xiaodan; Lin, Xiangjie; Wang, Jinghan

Journal: LEUKEMIA RESEARCH. 2026; Vol. 166, Issue , pp. -. DOI: 10.1016/j.leukres.2026.108232

2
Discovery of METTL3 inhibitor C191-0266 as a leukemia therapeutic through targeted modulation of protective autophag

Author:Hu, Xiaopeng; Zhu, Hua; Li, Chenyang

Journal: LEUKEMIA RESEARCH. 2026; Vol. 165, Issue , pp. -. DOI: 10.1016/j.leukres.2026.108167

3
Systemic evaluation for extramedullary disease and treatment outcomes in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemi

Author:Hou, Ruifeng; An, Lihong; Guan, Huanhuan; Lei, Xiao; Yang, Junhan; Zhang, Jinglan; Wu, Tong; Yu, Xinjian; Zheng, Qinlong; Liu, Shuangyou

Journal: LEUKEMIA RESEARCH. 2026; Vol. 165, Issue , pp. -. DOI: 10.1016/j.leukres.2026.108231

4
Development and temporal validation of an interpretable point score for in-hospital mortality in CLL/SLL using the US National Inpatient Sample, 2016-202

Author:Zhang, Xiaoyi; Bustamante, Jean; Stefani, Heloi; Lee, Howard; Xiao, Na; Xiao, Lisha; Soni, Anushri; Danpanichkul, Pojsakorn

Journal: LEUKEMIA RESEARCH. 2026; Vol. 164, Issue , pp. -. DOI: 10.1016/j.leukres.2026.108199

5
Measurable residual disease detection in acute leukemia: Technological advances and clinical translatio

Author:Wang, Meixin; Li, Jianfang

Journal: LEUKEMIA RESEARCH. 2026; Vol. 163, Issue , pp. -. DOI: 10.1016/j.leukres.2026.108197

6
Diagnostic updates and research advances in AML-MR: Integrating molecular genetics and immune mechanism

Author:Wang, Nan; Feng, Zuxi; Zheng, Hanxue; Chen, Xixi; Cong, Xiaofei; Zhang, Liansheng; Li, Lijuan

Journal: LEUKEMIA RESEARCH. 2026; Vol. 163, Issue , pp. -. DOI: 10.1016/j.leukres.2026.108200

7
Integrative transcriptomic and machine learning analysis identifies core immune genes and pathways driving graft-versus-host disease after allogeneic hematopoietic stem cell transplantatio

Author:Lu, Wei; He, Zhipeng; Huang, Xianbao

Journal: LEUKEMIA RESEARCH. 2026; Vol. 163, Issue , pp. -. DOI: 10.1016/j.leukres.2026.108201

8
Venetoclax and azacitidine versus CAG for unfit patients with newly diagnosed acute myeloid leukemia: A propensity score-matched analysi

Author:Chang, Guanghui; Gao, Haitao; Wei, Yan; Fu, Qiang; Jiang, Qian; Jiang, Hao; Xu, Lanping; Zhang, Xiaohui; Huang, Xiaojun; Tang, Feifei

Journal: LEUKEMIA RESEARCH. 2026; Vol. 163, Issue , pp. -. DOI: 10.1016/j.leukres.2026.108187

9
Frequency and prognostic significance of RAS pathway alterations in adult acute lymphoblastic leukemi

Author:Ou, Jiawang; Li, Jia; Liu, Qifa; Zhou, Hongsheng

Journal: LEUKEMIA RESEARCH. 2026; Vol. 160, Issue , pp. -. DOI: 10.1016/j.leukres.2025.108155

10
Assessing the associations of blood metabolites with myelodysplastic syndrome: A bidirectional mendelian randomization stud

Author:Hu, Keyue; Cheng, Yiquan; Xiao, Gangfeng; Shen, Xiu; Qian, Suying

Journal: LEUKEMIA RESEARCH. 2025; Vol. 155, Issue , pp. -. DOI: 10.1016/j.leukres.2025.107723


在线咨询

Leukemia Research

国际简称:LEUKEMIA RES参考译名:白血病研究

年发文量:73 CiteScore:4.1 是否预警:否 Gold OA文章占比:21.91% 研究类文章占比:95.89%

杂志社联系方式:PERGAMON-ELSEVIER SCIENCE LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND, OX5 1GB

Leukemia Research